Amedeo Smart

Free Medical Literature Service

 

Amedeo

Tuberculosis
  Free Subscription

Articles published in
Eur Respir J
    April 2024
  1. TRAUTH J, Kantelhardt V, Usenko B, Knipper M, et al
    Bedaquiline, pretomanid, and linezolid in multidrug-resistant and pre-extensively drug-resistant tuberculosis in refugees from Ukraine and Somalia in Germany.
    Eur Respir J. 2024 Apr 18:2400303. doi: 10.1183/13993003.00303-2024.
    >> Share

  2. NOGUERA-JULIAN A, Latre C, Flores A
    Availability of paediatric dispersible fixed-dose combinations of tuberculosis drugs in Spain.
    Eur Respir J. 2024;63:2400104.
    >> Share

    January 2024
  3. ALI M, El Hafid M, Farrar DS, Kourdi H, et al
    Travel-acquired paediatric tuberculosis in the Greater Toronto Area, Canada, 2002-2018.
    Eur Respir J. 2024 Jan 11:2301533. doi: 10.1183/13993003.01533-2023.
    >> Share


  4. "Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update." S. Ghosh, L. Breitscheidel, N. Lazarevic, et al. Eur Respir J 2021; 57: 2002483.
    Eur Respir J. 2024;63:2052483.
    >> Share

    November 2023
  5. ACHAR J, Seddon JA, Knight GM, Dodd PJ, et al
    Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing.
    Eur Respir J. 2023 Nov 9:2300969. doi: 10.1183/13993003.00969-2023.
    >> Share

  6. PERUMAL R, Bionghi N, Nimmo C, Letsoalo M, et al
    Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: A systematic review and meta-analysis.
    Eur Respir J. 2023 Nov 9:2300639. doi: 10.1183/13993003.00639-2023.
    >> Share

  7. ZENNER D, Cobelens F, Abubakar I
    Reply: Tuberculosis screening in migrants to the EU/EEA and UK.
    Eur Respir J. 2023;62:2301535.
    >> Share

  8. KOHLER N, Vasiliu A, Mandalakas AM, Martinez L, et al
    Tuberculosis screening in migrants to the EU/EEA and UK.
    Eur Respir J. 2023;62:2301230.
    >> Share

  9. DIEL R, Schluger NW
    Long-term outcome of co-infection of COVID-19 and tuberculosis: the "cursed duet".
    Eur Respir J. 2023;62:2301881.
    >> Share

  10. CASCO N, Jorge AL, Palmero DJ, Alffenaar JW, et al
    Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort.
    Eur Respir J. 2023;62:2300925.
    >> Share

    October 2023
  11. DEN BOON S, Yedilbayev A
    Screening for tuberculosis among migrants in Europe: harmonising approaches during a humanitarian crisis?
    Eur Respir J. 2023;62:2301537.
    >> Share

  12. AGUIAR SOARES K, Ehrlich J, Camara M, Chaloub S, et al
    Implementation of WHO guidelines on urine lateral flow LAM testing in high TB/HIV burden African countries.
    Eur Respir J. 2023;62:2300556.
    >> Share

  13. ZENNER D, Brals D, Nederby-Ohd J, Menezes D, et al
    Drivers determining tuberculosis disease screening yield in four European screening programmes: a comparative analysis.
    Eur Respir J. 2023;62:2202396.
    >> Share

    September 2023
  14. RIOU C, du Bruyn E, Kim GHJ, da Costa I, et al
    Derivation of a high-resolution CT-based, semi-automated radiographic score in tuberculosis and its relationship to bacillary load and antitubercular therapy.
    Eur Respir J. 2023 Sep 7:2300600. doi: 10.1183/13993003.00600-2023.
    >> Share

  15. BYRNE A, Allwood B, Schoeman I, Johnston J, et al
    "Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials.
    Eur Respir J. 2023;62:2300950.
    >> Share

    August 2023
  16. STOCKER SL, Alffenaar JC
    Predicting early bactericidal activity using pre-clinical data for tuberculosis drugs: a platform for model-informed drug discovery and development.
    Eur Respir J. 2023;62:2301108.
    >> Share

  17. ERNEST JP, Goh JJN, Strydom N, Wang Q, et al
    Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.
    Eur Respir J. 2023;62:2300165.
    >> Share

    June 2023
  18. MIGLIORI GB, Dowdy D, Denholm JT, D'Ambrosio L, et al
    The path to tuberculosis elimination: a renewed vision.
    Eur Respir J. 2023;61:2300499.
    >> Share


  19. June Podcast: Path to tuberculosis elimination.
    Eur Respir J. 2023;61:23E6106.
    >> Share

    May 2023
  20. KOSER CU, Maurer FP
    Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values for Mycobacterium tuberculosis complex.
    Eur Respir J. 2023;61:2202397.
    >> Share


  21. Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
    Eur Respir J. 2023;61:2300426.
    >> Share

  22. KAHLMETER G, Turnidge J
    The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series.
    Eur Respir J. 2023;61:2202259.
    >> Share

    November 2022
  23. OTTO-KNAPP R, Hacker B, Krieger D, Stete K, et al
    Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany.
    Eur Respir J. 2022;60:2200765.
    >> Share

    September 2022
  24. KIM C, Ko Y, Moon JW, Park YB, et al
    Incidence, risk factors, and final causes for misdiagnosis of tuberculosis in the Republic of Korea: a population-based longitudinal analysis.
    Eur Respir J. 2022 Sep 14. pii: 13993003.01461-2022.
    >> Share

    August 2022
  25. SALUZZO F, Denkinger CM, Cirillo DM
    Improving interferon-gamma release assay interpretation: are IP-10 and MIG the solution?
    Eur Respir J. 2022;60.
    >> Share

  26. ROCHE N, Crichton ML, Goeminne PC, Cao B, et al
    Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.
    Eur Respir J. 2022;60.
    >> Share

    July 2022
  27. MATTEELLI A, Alffenaar JC
    Diagnosis and treatment of tuberculosis infection: can it contribute to achieving tuberculosis elimination?
    Eur Respir J. 2022;60.
    >> Share

  28. MASINI T, Kanchar A, Mirzayev F, Viney K, et al
    Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.
    Eur Respir J. 2022 Jul 1. pii: 13993003.01227-2022.
    >> Share

    June 2022
  29. CHUNG C, Shin JE, Jeon D, Kang H, et al
    Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease.
    Eur Respir J. 2022 Jun 16. pii: 13993003.00930-2022.
    >> Share

    May 2022
  30. MANTEI A, Meyer T, Schurmann M, Bessler C, et al
    Mycobacterium tuberculosis-specific CD4 T-cell scoring discriminates tuberculosis infection from disease.
    Eur Respir J. 2022 May 26. pii: 13993003.01780-2021.
    >> Share

  31. AHMED M, Tezera LB, Elkington PT, Leslie AJ, et al
    The paradox of immune checkpoint inhibition reactivating tuberculosis.
    Eur Respir J. 2022 May 20. pii: 13993003.02512-2021.
    >> Share

  32. GUGLIELMETTI L, Gunther G, Leu C, Cirillo D, et al
    Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
    Eur Respir J. 2022;59.
    >> Share

  33. SPRUIJT I, Joren C, Schimmel H, Procee F, et al
    The identification of prevalent tuberculosis disease through infection screening among high-risk migrants in the Netherlands.
    Eur Respir J. 2022;59.
    >> Share

    April 2022
  34. DAHL V, Migliori GB, Lange C, Wejse C, et al
    War in Ukraine: an immense threat to the fight against tuberculosis.
    Eur Respir J. 2022;59.
    >> Share


  35. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.
    Eur Respir J. 2022;59.
    >> Share

    March 2022

  36. Epidemiological cutoff values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
    Eur Respir J. 2022 Mar 17. pii: 13993003.00239-2022.
    >> Share

  37. MIGLIORI GB, Falzon D, Marks GB, Goletti D, et al
    Commemorating World Tuberculosis Day 2022: recent ERJ articles of critical relevance to ending TB and saving lives.
    Eur Respir J. 2022;59.
    >> Share

  38. TORNHEIM JA, Udwadia ZF, Arora PR, Gajjar I, et al
    Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis.
    Eur Respir J. 2022;59.
    >> Share

    February 2022
  39. DINARDO AR, Gandhi T, Heyckendorf J, Grimm SL, et al
    Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes.
    Eur Respir J. 2022 Feb 15. pii: 13993003.02263-2021.
    >> Share

    January 2022
  40. MARGINEANU I, Akkerman O, Cattaneo D, Goletti D, et al
    Practices of therapeutic drug monitoring in tuberculosis - an international survey.
    Eur Respir J. 2022 Jan 27. pii: 13993003.02787-2021.
    >> Share

  41. FALZON D, den Boon S, Kanchar A, Zignol M, et al
    Global reporting on tuberculosis preventive treatment among contacts.
    Eur Respir J. 2022 Jan 27. pii: 13993003.02753-2021.
    >> Share

  42. UZORKA JW, Bakker JA, van Meijgaarden KE, Leyten EMS, et al
    Biomarkers to identify Mycobacterium tuberculosis-infection among borderline QuantiFERON results.
    Eur Respir J. 2022 Jan 20. pii: 13993003.02665-2021.
    >> Share

    November 2021
  43. GHODOUSI A, Rizvi AH, Khanzada FM, Akhtar N, et al
    In vivo Microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient.
    Eur Respir J. 2021 Nov 18. pii: 13993003.02102-2021.
    >> Share


  44. Tuberculosis and COVID-19 co-infection: description of the global cohort.
    Eur Respir J. 2021 Nov 11. pii: 13993003.02538-2021.
    >> Share

  45. XIN H, Cao X, Zhang H, Feng B, et al
    Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial.
    Eur Respir J. 2021 Nov 11. pii: 13993003.02359-2021.
    >> Share

  46. ZHENG X, Davies Forsman L, Bao Z, Xie Y, et al
    Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug resistant tuberculosis: a multi-centre prospective cohort study in China.
    Eur Respir J. 2021 Nov 4. pii: 13993003.01925-2021.
    >> Share

    October 2021
  47. GUPTE AN, Kumar P, Araujo-Pereira M, Kulkarni V, et al
    Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study.
    Eur Respir J. 2021 Oct 28. pii: 13993003.00905-2021.
    >> Share

  48. SALUZZO F, Mantegani P, Poletti de Chaurand V, Cirillo DM, et al
    QIAreach QuantiFERON(R)-TB for the diagnosis of M. tuberculosis infection.
    Eur Respir J. 2021 Oct 21. pii: 13993003.02563-2021.
    >> Share

    September 2021
  49. SPRUIJT I, Joren C, van den Hof S, Erkens C, et al
    Tailored approaches facilitate high completion of tuberculosis infection treatment among migrants.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02077-2021.
    >> Share

  50. DECROO T, Jai K, Aung M, Hossain MA, et al
    Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02124-2021.
    >> Share

  51. CHESOV E, Chesov D, Maurer FP, Andres S, et al
    Emergence of bedaquiline-resistance in a high-burden country of tuberculosis.
    Eur Respir J. 2021 Sep 9. pii: 13993003.00621-2021.
    >> Share

    August 2021
  52. MIGLIORI GB, Thong PM, Alffenaar JW, Denholm J, et al
    Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study.
    Eur Respir J. 2021 Aug 26. pii: 13993003.01786-2021.
    >> Share

  53. LINH NN, Viney K, Gegia M, Falzon D, et al
    World Health Organization treatment outcome definitions for tuberculosis: 2021 update.
    Eur Respir J. 2021;58.
    >> Share

    July 2021
  54. ALAGNA R, Cabibbe AM, Miotto P, Saluzzo F, et al
    Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?
    Eur Respir J. 2021;58.
    >> Share

  55. TE BRAKE LHM, de Jager V, Narunsky K, Vanker N, et al
    Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin.
    Eur Respir J. 2021;58.
    >> Share

    June 2021
  56. KHAN PY, Franke MF, Hewison C, Seung KJ, et al
    All-oral longer regimens are effective for the management of multidrug resistant tuberculosis in high burden settings.
    Eur Respir J. 2021 Jun 17. pii: 13993003.04345-2020.
    >> Share

  57. SAAVEDRA B, Mambuque E, Nguenha D, Gomes N, et al
    Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding.
    Eur Respir J. 2021 Jun 17. pii: 13993003.00257-2021.
    >> Share

  58. ORIKIRIZA P, Smith J, Ssekyanzi B, Nyehangane D, et al
    Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children.
    Eur Respir J. 2021 Jun 17. pii: 13993003.01116-2021.
    >> Share

  59. SHIVAKOTI R, Newman JW, Hanna LE, Queiroz ATL, et al
    Host Lipidome and Tuberculosis Treatment Failure.
    Eur Respir J. 2021 Jun 17. pii: 13993003.04532-2020.
    >> Share

  60. VILLA S, Tagliani E, Borroni E, Castellotti PF, et al
    Outbreak of pre- and extensively drug-resistant tuberculosis in northern italy: urgency of cross-border, multidimensional, surveillance systems.
    Eur Respir J. 2021 Jun 3. pii: 13993003.00839-2021.
    >> Share

  61. GUGLIELMETTI L, Varaine F
    The coming-of-age of bedaquiline: a tale with an open ending.
    Eur Respir J. 2021;57.
    >> Share

    May 2021
  62. PENN-NICHOLSON A, Gomathi SN, Ugarte-Gil C, Meaza A, et al
    A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays.
    Eur Respir J. 2021 May 28. pii: 13993003.00526-2021.
    >> Share

  63. NOGUERA-JULIAN A, Buonsenso D, Mckenna L, Seddon JA, et al
    Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe.
    Eur Respir J. 2021 May 28. pii: 13993003.01196-2021.
    >> Share

  64. VELEN K, Shingde RV, Ho J, Fox GJ, et al
    The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis.
    Eur Respir J. 2021 May 20. pii: 13993003.00266-2021.
    >> Share

  65. WEE LE, Goh KCM, Conceicao EP, Tan JBX, et al
    Increased detection of pulmonary tuberculosis amongst hospitalised inpatients during the COVID-19 pandemic.
    Eur Respir J. 2021;57.
    >> Share

  66. GHOSH S, Breitscheidel L, Lazarevic N, Martin A, et al
    Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
    Eur Respir J. 2021;57.
    >> Share

  67. MAYNARD-SMITH L, Brown CS, Harris RJ, Hodkinson P, et al
    Effectiveness and outcomes of air travel-related TB incident follow-up: a systematic review.
    Eur Respir J. 2021;57.
    >> Share

    April 2021
  68. VEZIRIS N, Bonnet I, Morel F, Guglielmetti L, et al
    Impact of the revised definition of extensively drug resistant tuberculosis.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00641-2021.
    >> Share

  69. MUYOYETA M, Kerkhoff AD, Chilukutu L, Moreau E, et al
    Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study.
    Eur Respir J. 2021 Apr 29. pii: 13993003.03999-2020.
    >> Share

  70. VAN DEUN A, Decroo T, Aung KJM, Hossain MA, et al
    Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00783-2021.
    >> Share

  71. HAMADA Y, Cirillo DM, Matteelli A, Penn-Nicholson A, et al
    Tests for tuberculosis infection: landscape analysis.
    Eur Respir J. 2021 Apr 19. pii: 13993003.00167-2021.
    >> Share

  72. VINEY K, Linh NN, Gegia M, Zignol M, et al
    New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.
    Eur Respir J. 2021;57.
    >> Share

  73. SRIVASTAVA S, Gumbo T
    Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis.
    Eur Respir J. 2021;57.
    >> Share

  74. MAITRE T, Guglielmetti L, Veziris N
    Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies.
    Eur Respir J. 2021;57.
    >> Share

  75. NORDHOLM AC, Lillebaek T
    It is time to optimise the management of latent tuberculosis infection in children.
    Eur Respir J. 2021;57.
    >> Share

    March 2021
  76. BOHLBRO AS, Hvingelby VS, Rudolf F, Wejse C, et al
    Active case-finding of tuberculosis in general populations and at-risk groups: a systematic review and meta-analysis.
    Eur Respir J. 2021 Mar 25. pii: 13993003.00090-2021.
    >> Share

  77. GUPTA RK, Lule SA, Krutikov M, Gosce L, et al
    Screening for tuberculosis among high-risk groups attending London Emergency Departments: A prospective observational study.
    Eur Respir J. 2021 Mar 18. pii: 13993003.03831-2020.
    >> Share

  78. DE VRIES G, Gainaru D, Keizer S, Mahler B, et al
    Human reading versus computer automated reading of chest X-rays in a tuberculosis screening programme in Romania.
    Eur Respir J. 2021 Mar 10. pii: 13993003.04628-2020.
    >> Share

  79. JOUET A, Gaudin C, Badalato N, Allix-Beguec C, et al
    Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs.
    Eur Respir J. 2021;57.
    >> Share

    February 2021
  80. HEYCKENDORF J, Marwitz S, Reimann M, Avsar K, et al
    Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
    Eur Respir J. 2021 Feb 11. pii: 13993003.03492-2020.
    >> Share

  81. ZHANG N, Savic RM, Boeree MJ, Peloquin C, et al
    Optimising pyrazinamide for the treatment of tuberculosis.
    Eur Respir J. 2021 Feb 4. pii: 13993003.02013-2020.
    >> Share

  82. KOHLI M, MacLean E, Pai M, Schumacher SG, et al
    Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis.
    Eur Respir J. 2021;57.
    >> Share

    January 2021
  83. HAMADA Y, den Boon S, Maria Cirillo D, Penn-Nicholson A, et al
    Framework for the evaluation of new tests for tuberculosis infection.
    Eur Respir J. 2021 Jan 21. pii: 13993003.04078-2020.
    >> Share

  84. SOULEYMANE MB, Piubello A, Lawan IM, Hassane-Harouna S, et al
    High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Eur Respir J. 2021;57.
    >> Share

  85. RADTKE KK, Hibma JE, Hesseling AC, Savic RM, et al
    Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
    Eur Respir J. 2021;57.
    >> Share

    December 2020
  86. CHESOV D, Heyckendorf J, Alexandru S, Donica A, et al
    Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
    Eur Respir J. 2020 Dec 17. pii: 13993003.02544-2020.
    >> Share

    November 2020
  87. MIRZAYEV F, Viney K, Linh NN, Gonzalez-Angulo L, et al
    World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
    Eur Respir J. 2020 Nov 26. pii: 13993003.03300-2020.
    >> Share

  88. NIKOLAYEVSKYY V, Holicka Y, van Soolingen D, van der Werf MJ, et al
    Impact of COVID-19 pandemic on tuberculosis laboratory services in Europe.
    Eur Respir J. 2020 Nov 12. pii: 13993003.03890-2020.
    >> Share

  89. DAVIES FORSMAN L, Niward K, Kuhlin J, Zheng X, et al
    Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
    Eur Respir J. 2020 Nov 5. pii: 13993003.03463-2020.
    >> Share

  90. GEBRESELASSIE N, Kasaeva T, Zignol M
    A global strategy for tuberculosis research and innovation.
    Eur Respir J. 2020;56.
    >> Share

    October 2020
  91. MANDALAKAS AM, Hesseling AC, Kay A, Du Preez K, et al
    Tuberculosis prevention in children: A prospective community based study in South Africa.
    Eur Respir J. 2020 Oct 29. pii: 13993003.03028-2020.
    >> Share

  92. GUPTA N, Ish P, Gupta A, Malhotra N, et al
    A profile of a retrospective cohort of 22 patients of COVID-19 with active/treated tuberculosis.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03408-2020.
    >> Share

  93. KWON YS, Jeon D, Kang H, Yim JJ, et al
    Concurrent Use of Bedaquiline and Delamanid for the Treatment of Fluoroquinolone-resistant Multidrug-resistant Tuberculosis: A Nationwide Cohort Study in South Korea.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03026-2020.
    >> Share

    September 2020
  94. CHIANG CY, Islam T, Xu C, Chinnayah T, et al
    The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region (revised).
    Eur Respir J. 2020 Sep 25. pii: 13993003.03054-2020.
    >> Share

    May 2020
  95. WONG YJ, Lee SWH
    We must screen refugees to ensure no one is left behind: a case study of Malaysia.
    Eur Respir J. 2020;55.
    >> Share

  96. VAN DEN ELSEN SHJ, Akkerman OW, Jongedijk EM, Wessels M, et al
    Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
    Eur Respir J. 2020;55.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016